Siren L.L.C. Purchases Shares of 3,457,711 CytomX Therapeutics, Inc. $CTMX

Siren L.L.C. purchased a new position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the 1st quarter, Holdings Channel.com reports. The fund purchased 3,457,711 shares of the biotechnology company’s stock, valued at approximately $16,251,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wells Fargo & Company MN grew its stake in shares of CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 3,000 shares in the last quarter. Invesco Ltd. acquired a new position in CytomX Therapeutics during the second quarter worth $32,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in CytomX Therapeutics during the fourth quarter worth $35,000. Goldman Sachs Group Inc. bought a new stake in CytomX Therapeutics during the first quarter worth $39,000. Finally, May Hill Capital LLC bought a new stake in CytomX Therapeutics during the fourth quarter worth $46,000. Institutional investors own 67.77% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on CTMX shares. Zacks Research raised shares of CytomX Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Wolfe Research initiated coverage on shares of CytomX Therapeutics in a report on Tuesday, May 19th. They issued an “outperform” rating and a $6.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of CytomX Therapeutics in a report on Tuesday, June 16th. HC Wainwright cut their target price on shares of CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Finally, Wall Street Zen upgraded CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $12.10.

CytomX Therapeutics Stock Performance

CTMX opened at $3.33 on Friday. The stock’s fifty day simple moving average is $3.44 and its 200 day simple moving average is $4.35. CytomX Therapeutics, Inc. has a 1-year low of $1.72 and a 1-year high of $8.21. The stock has a market cap of $566.73 million, a PE ratio of -8.12 and a beta of 2.08.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. CytomX Therapeutics had a negative net margin of 166.40% and a negative return on equity of 36.61%. The firm had revenue of $10.26 million during the quarter, compared to analysts’ expectations of $4.68 million. Equities analysts forecast that CytomX Therapeutics, Inc. will post -0.45 earnings per share for the current year.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.